Expression and Prognostic Value of the Immune Checkpoints Galectin-9 and PD-L1 in Glioblastomas
- 15 May 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 80 (6) , 541-551
Abstract
Immunotherapeutic targeting of the PD-1/PD-L1 axis has been widely implemented for treatment of several cancer types but shown disappointing results in glioblastomas (GBMs), potentially due to compensatory mechanisms of other expressed immune checkpoints. Galectin-9 is an immune-checkpoint protein that facilitates T-cell exhaustion and apoptosis and could be a potential target for immune-checkpoint inhibition. A total of 163 GBMs IDH wildtype were immunostained with anti-Galectin-9 and PD-L1 antibodies. Software-based quantitation of immunostainings was performed and co-expression was investigated using double immunofluorescence. Both Galectin-9 and PD-L1 protein expression were found in all 163 tumors and showed a significant positive correlation (p = 0.0017). Galectin-9 expression varied from 0.01% to 32% (mean = 6.61%), while PD-L1 membrane expression ranged from 0.003% to 0.14% (mean = 0.048%) of total tumor area. Expression of Galectin-9 and PD-L1 was found on both microglia/macrophages and tumor cells, and colocalization of both markers was found in 88.3% of tumors. In multivariate analysis, neither Galectin-9 (HR = 0.99), PD-L1 (HR = 1.05), nor their combinations showed prognostic value. Galectin-9 and PD-L1 were expressed in all investigated GBMs and the majority of patients had co-expression, which may provide rationale for multi-targeted immune checkpoint inhibition.Keywords
This publication has 52 references indexed in Scilit:
- Glioblastoma: Defining Tumor NichesTrends in Cancer, 2015
- PD-L1 expression and prognostic impact in glioblastomaNeuro-Oncology, 2015
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain TumorsClinical Cancer Research, 2014
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapyJournal of Experimental Medicine, 2014
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer PatientsCancer Research, 2013
- Immunologic Privilege in the Central Nervous System and the Blood–Brain BarrierJournal of Cerebral Blood Flow & Metabolism, 2012
- Challenges in Immunotherapy Presented by the Glioblastoma Multiforme MicroenvironmentJournal of Immunology Research, 2011
- Galectins and GliomasBrain Pathology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Structural Features of Galectin-9 and Galectin-1 That Determine Distinct T Cell Death PathwaysJournal of Biological Chemistry, 2008